Regulated information

2008 Interim Revenues increase by 5%

Vétoquinol generated revenues of 116.7 million euros in the first half of 2008, a 5% increase over the 111.1 million euros
reported the previous year.

2010 annual earnings

Lure (France), April 4, 2011 – Vétoquinol’s Board of Directors, meeting on March 18, 2011, has reviewed the Group’s business and approved its 2010 financial statements.

2010 Revenues grow 11.8%, driven by organic growth

The Vétoquinol Group reports sustained sales growth driven by its “hybrid” business model, supported by a sound level of organic growth.

Earnings for 2007 attest to strength of business growth model

The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance
indicators, ahead of its medium-term targets. According to the most recent statistics published by Vetnosis, this substantial rise in revenue has lifted Vétoquinol to third place
worldwide.

European launch of new Nsaid Cimalgex®

Lure (France), June 14, 2011 – Vetoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.

Forcyl®: european launch of new drug

Lure (France), September 29, 2011 – Vétoquinol announces the European launch of Forcyl®, a new drug based on 16% concentrated marbofloxacin allowing the treatment of cattle respiratory infections with a single injection.

International expansion and new product launches

Lure (France), July 19, 2011 – Vétoquinol Group sales rose to €139.7 million in the first six months of 2011.

Jacques du Puy appointed Vétoquinol Managing Director

Lure (France), October 12, 2011 – The Vétoquinol Group announces the appointment
of Jacques du Puy as Managing Director.

KIBOW BIOTECH INC. et Vétoquinol S.A. étendent leur accord de commercialisation et de licence vétérinaire pour des applications mondiales (french)

Mis en oeuvre des recommandations AFEP/MEDEF du 6 octobre 2008 sur les rémunérations des dirigeants mandataires sociaux des sociétés cotées

Lors de sa réunion du 5 décembre 2008, le Conseil d’administration a pris connaissance des recommandations AFEP-MEDEF du 8 octobre 2008 sur la rémunération des dirigeants sociaux des sociétés cotées.